Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: margie who wrote (5636)	11/4/1998 10:49:00 AM
From: Joe E.	of 6136

Clearly the fusion inhibitor has the potential to eventually take some market share from the protease inhibitors. Effects should be minimal so long as the drug requires injection. Pill form fusion inhibitors are not in the cards for several years, if then. Side effects (particularly the longer term ones that bother current triple therapy patients) are largely unknown at this point, although gross safety has been tested for the injection product. News stories about alternative HIV treatments seem to almost always knock AGPH stock back for a while. IMO most of us think that Viracept will eventually be replaced by something else, but it sure looks like it will be a long time before that happens, right now.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next